**Exhibit 10.2**

 

THIS CONVERTIBLE PROMISSORY NOTE (THIS “NOTE”) AND THESECURITIES THAT MAY BE ACQUIRED PURSUANT TO THIS NOTE HAVE NOT BEENREGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIESACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOTBE OFFERED, SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSEDOF WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, ANY U.S.PERSON, OTHER THAN DISTRIBUTORS (AS DEFINED IN REGULATION S PROMULGATED UNDERTHE SECURITIES ACT), IN THE ABSENCE OF SUCH REGISTRATION, UNLESS SUCHTRANSACTION IS EXEMPT FROM OR NOT SUBJECT TO REGISTRATION UNDER THE SECURITIESACT, AND HOLDER HAS, IF REQUIRED BY THE COMPANY, DELIVERED AN OPINION OFCOUNSEL TO THAT EFFECT.  BY ACCEPTING THIS NOTE, HOLDER REPRESENTS, AMONGOTHER THINGS, THAT IT IS AN ACCREDITED INVESTOR (AS DEFINED IN RULE 501(a) OFTHE SECURITIES ACT) AND IS NOT A U.S PERSON, AND IS ACQUIRING THIS NOTE ANDWILL ACQUIRE ANY CONVERSION SHARES (AS DEFINED HEREIN) OUTSIDE THE U.S. AND INACCORDANCE WITH REGULATION S, AND WILL NOT ENGAGE IN ANY HEDGING TRANSACTIONSWITH RESPECT TO THIS NOTE OR THE COMMON STOCK OF THE COMPANY PRIOR TO THEEXPIRATION OF THE DISTRIBUTION COMPLIANCE PERIOD (AS DEFINED HEREIN) EXCEPT INCOMPLIANCE WITH THE SECURITIES ACT.  ISSUANCE OF THE CONVERSION SHARES ISCONDITIONED UPON THE CONTINUED AVAILABILITY OF REGULATION S IN RESPECT OFHOLDER AT TIME OF CONVERSION, OR THE AVAILABILITY TO HOLDER OF ANOTHEREXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT IN RESPECT OF SUCHISSUANCE.

 

**CONVERTIBLE PROMISSORY NOTE**

 
|  **US $                  ** | ** ** | **                    ,  2008** |
|----------------------------------------------------------------------------------------------------------------------------|------------|-------------------------------------------------------------------------------------------------------------------------------------|

 

FOR VALUE RECEIVED, **OsirisTherapeutics, Inc.** , a Delaware corporation (the “ **Company** “), having an address of 7015Albert Einstein Drive, Columbia, MD, U.S.A., hereby promises to pay to theorder of                                 (the “ **Holder** “), at the officesof Holder at                                 or such other place as may be designated by Holder to the Company in writing,the aggregate principal amount of                                                     **U.S. Dollars****($                   )**(the “ **Principal** “) together withaccrued and unpaid interest, upon the terms and conditions hereinafter setforth.

 

1.                                       Payment Terms.  The Company promises to pay toHolder the Final Payment Amount (as hereinafter defined) on **November 30 , 2009**(the “ **Maturity Date** “), unlessthis Note is earlier redeemed by the Company or converted into Common Stock (ashereinafter defined) of the Company, pursuant to Section 3 hereof,as applicable.  All accrued and unpaid interest shall be due and payablein accordance with Section 2 hereof.  All payments hereundershall be made in lawful money of the United States of America. Payment shall becredited first to the accrued and unpaid interest then due and payable and theremainder to Principal.  “Final Payment Amount” means an amount equal tothe sum of the total unpaid Principal plus any accrued and unpaid interest.

 

2.                                       Interest.  Interest on the outstanding portion ofPrincipal of this Note shall accrue at a rate of **two percent (2%) per annum**.  All computations of interestshall be made on the basis of a 360-day year for actual days elapsed.  Allaccrued interest shall be due and payable in cash on the Maturity Date, the Redemption Date (as hereinafter defined) or Conversion Date (as hereinafterdefined), as the case may be, in each case in accordance with the terms andconditions of this Note. Any accrued but unpaid interest will be paid in cashat the time of conversion. If the Maturity Date, the Redemption Date or theConversion

 

March      , 2008 ConvertiblePromissory Note 

 

1

----

 

Date, be on a day that is not a business day, paymentof any amounts due and payable on such date shall be effected on theimmediately following business day.

 

3.                                       Conversion or Redemption of this Note .

 

(a)                                                                                  Conversion.  This Note is convertible into shares of CommonStock at any time at the sole discretion of the Holder. Upon receipt of awritten request for conversion of this Note upon the Company, the “Conversion**Date**,” this Note shall be converted in itsentirety and not in part into shares of the Common Stock.  The number ofshares of Common Stock to which Holder shall be entitled upon such conversionshall be equal to the sum of the total unpaid principal divided by the ClosingPrice of the Common Stock, as reported on the NASDAQ Global Market on March       ,2008 (the “Note**Conversion Rate**”).Any accrued but unpaid interest will be paid in cash at the time of conversion.For purposes of this paragraph 3(a), the term Closing Price shall mean, asreasonably determined by the Company, the reported closing price on the NASDAQGlobal Market on March       , 2008.

 

(b)                                                                                 Redemption.  This Note may be redeemed by the Company atany time by payment to Holder in immediately available funds of the sum of thetotal unpaid principal plus any accrued but unpaid interest.  The Companymust provide written notice to Holder not less than 30 days prior to theeffective date of such redemption (the “Redemption**Date**”).

 

©                                                                                      No Fractional Shares.  The number of Common Sharesresulting from a conversion of this Note pursuant to Section 3(a) aboveshall be rounded up to the next higher integral share of Common Stock, and nofractional shares shall be issuable by the Company upon conversion of thisNote.  Conversion of this Note shall be deemed payment in full of thisNote and this Note shall thereupon be cancelled.

 

4.                                       The indebtedness evidenced hereby rankspari passu in right of payment to the indebtedness evidenced from time to timeby the other of the Offered Notes (as defined below) and to any otherconvertible debt securities of the Company now or hereafter existing and soproviding, and the indebtedness evidenced hereby ranks senior in right ofpayment to all classes and series of the Company’s capital stock.  Byaccepting this Note the Holder does expressly consent to the aforesaid rankingin right of payment and agrees to perform, from time to time, such acts, and toexecute, acknowledge and/or deliver such other instruments, documents andagreements, as may from time to time be requested by the Company, or as mayfrom time to time otherwise be reasonably requested, necessary or required, toso confirm or provide.

 

5.                                       Representations and Warranties of the Company.  The Company represents andwarrants to Holder as follows:

 

(a)                                                                                  The execution and delivery by the Companyof this Note (i) are within the Company’s corporate power and authority,and (ii) have been duly authorized by all necessary corporate action.

 

(b)                                                                                 This Note is a legally binding obligationof the Company, enforceable against the Company in accordance with the termshereof, except to the extent that (i) such enforceability is limited bybankruptcy, insolvency, reorganization, moratorium or other laws relating to oraffecting generally the enforcement of creditors’ rights, and (ii) theavailability of the remedy of specific performance or in injunctive or otherequitable relief is subject to the discretion of the court before which anyproceeding therefore may be brought.

 

2

----

 

6.                                       Use of Proceeds.  The proceeds received by theCompany from the sale of this Note shall be used by the Company for workingcapital, redemption or repayment of debt or other general corporate purposes.

 

7.                                       No Waiver in Certain Circumstances.  No course of dealing of Holdernor any failure or delay by Holder to exercise any right, power or privilegeunder this Note shall operate as a waiver hereunder and any single or partialexercise of any such right, power or privilege shall not preclude any laterexercise thereof or any exercise of any other right, power or privilegehereunder.

 

8.                                       Certain Waivers by the Company.  Except as expressly providedotherwise in this Note, the Company and every endorser or guarantor, if any, ofthis Note waive presentment, demand, notice, protest and all other demands andnotices in connection with the delivery, acceptance, performance, default orenforcement of this Note, and assent to any extension or postponement of thetime of payment or any other indulgence, to any substitution, exchange orrelease of collateral available to Holder, if any, and to the addition orrelease of any other party or person primarily or secondarily liable.

 

9.                                       No Unlawful Interest.  Notwithstanding anything hereinto the contrary, payment of any interest or other amount hereunder shall not berequired if such payment would be unlawful.  In any such event, this Noteshall automatically be deemed amended so that interest charges and all otherpayments required hereunder, individually and in the aggregate, shall be equalto but not greater than the maximum permitted by law.  As a condition toits obligation to make any payment of interest hereunder without withholding asmay otherwise be required under applicable U.S. tax laws, the Company mayrequire that the Holder submit to the Company a properly completed IRS Form W-8or similar or successor form sufficiently demonstrating to the reasonablesatisfaction of the Company that no such withholding is required.

 

10.                                 Representations, Warranties andCovenants of Holder .  By accepting this Note, Holder represents andwarrants to the Company, and agrees, as follows:

 

(a)                                                                                  The principal address of Holder isoutside of the United States, and Holder is not a U.S. Person as such term isdefined and used in Regulation S.

 

(b)                                                                                 At the time the “buy” order wasoriginated in respect of Holder’s acquisition of this Note, Holder was outsideof the U.S., and Holder is outside the U.S. as of the date of the execution anddelivery of this Note by Holder.  No offer to acquire this Note was madeto Holder or its representatives inside the United States.

 

(c)                                                                                  Holder is an “accredited investor” withinthe meaning of Rule 501(a) under the Securities Act.

 

(d)                                                                                 Holder is acquiring this Note and willacquire any Conversion Shares for his/her/its own account, not on behalf or forthe account of any U.S. Person, and neither the purchase of this Note nor theacquisition of the Conversion Shares has been pre-arranged with a purchaser inthe U.S.

 

(e)                                                                                  The Holder will make all resales of thisNote and any Conversion Shares only outside of the United States in compliancewith Regulation S, or pursuant to a registration statement under the SecuritiesAct, or pursuant to an available exemption from registration under theSecurities Act.  Specifically, Holder will not resell this Note or anyConversion Shares to any U.S. Person or within the United States prior to theexpiration of one year (the “Distribution **CompliancePeriod** “) after the closing of the offering to which this Noterelates, except pursuant to registration under the Securities Act or anexemption from registration under the Securities Act.

 

3

----

 

(f)                                                                                    Holder will not engage in any hedgingtransactions with respect to this Note or the Common Stock of the Company atany time prior to the expiration of the Distribution Compliance Period, exceptin compliance with the Securities Act.

 

(g)                                                                                 The Company is and will be relying on thetruth and accuracy of Holder’s representations, warranties, agreements,acknowledgements and understandings as set forth herein, in order to determinethe applicability of such exemptions and the suitability of Holder andhis/her/its acquisition of the Note and Conversion Shares upon conversionhereof.

 

(h)                                                                                  Holder has been furnished with, or hasacquired, copies of all of the documents filed by the Company with the UnitedStates Securities and Exchange Commission during the twelve months prior to thedate hereof, as well as all other documents made available by the Company forpublic dissemination during the same period, including, but not limited to,press releases, and Holder has been provided all necessary and appropriateinformation about the Company to make an informed investment decision withrespect to the acquisition of this Note.

 

(i)                                                                                     Holder has sufficient knowledge andexperience in financial and business matters and is capable of evaluating therisks and merits of Holder’s investment in the Company; Holder has beenprovided the opportunity to make all necessary and appropriate inquiries of theCompany regarding Company’s business and associated risks, and Company hascomplied with all such requests; and Holder is able financially to bear therisk of losing Holder’s full investment in this Note.

 

(j)                                                                                     The Note is being acquired and anyConversion Shares will be acquired in a transaction not involving a publicoffering within the United States within the meaning of the Securities Act, andHolder understands that this Note has not been and will not be, and anyConversion Shares have not been and may not be, registered under the SecuritiesAct or registered or qualified under any the securities laws of any state orother jurisdiction, are and will be “restricted securities” and cannot beresold or otherwise transferred unless they are registered under the SecuritiesAct, and registered or qualified under any other applicable securities laws, oran exemption from such registration and qualification is available.  Priorto any proposed transfer of this Note or any Conversion Shares, Holder shall,among other things, give written notice to the Company of Holder’s intention toeffect such transfer, identifying the transferee and describing the manner ofthe proposed transfer and, if requested by the Company, accompanied by (i) investmentrepresentations by the transferee similar to those made by Holder in this Section 10and (ii) an opinion of counsel satisfactory to the Company to the effectthat the proposed transfer may be effected without registration under theSecurities Act and without registration or qualification under applicable stateor other securities laws.  Each certificate for any Conversion Sharesshall bear a legend  similar to that set forth on Page 1 of this Note(insofar as applicable) and otherwise referring to reiterating the restrictionson transfer and other terms hereof applicable to the Conversion Shares uponissuance.

 

(k)                                                                                  Holder understands that no U.S. federalor state government or agency has passed on or made any recommendation orendorsement of offering for sale or the sale of this Note, or with respect tothe Conversion Shares.

 

(l)                                                                                     Holder acknowledges that this Note is oneof several similar notes (collectively the “ **OfferedNotes**”) in theaggregate principal amount of up to $10000,000, or at the option of theCompany, a greater amount; and that there is no restriction imposed hereby uponthe Company in respect of the incurring by the Company of additional debt orthe issuance by the Company of additional debt or equity securities, orotherwise.

 

4

----

 

11.                                 Anti-dilution.  If the Company executes a stocksplit, reverse stock split, or re-capitalization, or makes a dividend or otherdistribution in cash or shares on Common Stock, or reclassifies all or part ofits outstanding Common Stock (any of the foregoing a “ **Dilution Transaction** ”), the NoteConversion Rate and Threshold Amount specified in Section 3(a) aboveshall each be equitably and proportionately adjusted so that this Note shall beconverted as of the same date as it would have otherwise converted had suchDilution Transaction not occurred, and so that the Holder of this Note shallupon conversion following a Dilution Event be entitled to receive the numberand kind of shares of Common Stock that such Holder would have owned or havebeen entitled to receive immediately prior to the happening of a DilutionTransaction and then, following such conversion, subsequently subjected to theeffect thereof.

 

12.                                 Registration.   Upon therequest of Holder or of any holder of any of the other Offered Notes(collectively, the “ **Offered Noteholders**”following the first to occur of the conversion of this Note and the conversionof any of the Offered Notes and the issuance of Conversion Shares hereunder orthereunder and as defined therein, and provided that the Company shall then be,or if not, at such time thereafter as the Company shall become, eligible toeffect the registration pursuant to the Securities Act of the shares of CommonStock issued or issuable hereunder or upon conversion of the other OfferedNotes (collectively, the “ **Registrable Securities** ”)on Form S-3 or on another  “short form” registration statement, theCompany shall use commercially reasonable efforts to effect registrationpursuant to the Securities Act, of the Registrable Securities or the resalethereof by the Offered Holders on Form S-3 or on another short formregistration statement.  The Company shall have no obligation hereunder toeffect any such registration at any time which, as determined by the Company,neither Form S-3 nor any other similar short-form registration statementis available therefor, nor shall the Company have any obligation to maintainthe effectiveness of such registration statement for more than one year. The Company may delay the filing of any such registration statement as a resultof constraints or restrictions under applicable law so requiring as determinedby the Company, or suspend the effectiveness of any such registration statementand/or require by written notice that the Offered Noteholders immediately ceasesales of shares in the event that from time to time (i) the Company filesanother registration statement (other than a registration statement on Form S-8or its successor form) under the Securities Act for a then pending oranticipated public offering of its securities, or (ii) an event hasoccurred, or the Company has entered into a transaction, which the Companydetermines in good faith must be disclosed in order for the Company to complywith the public disclosure requirements imposed on the Company under the SecuritiesAct.  The Company shall not be required to include any RegistrableSecurities in any such registration statement unless the Holder (i) providesto the Company in a timely manner such information regarding the Holder as isrequired by the Securities Act to be included in the registration statement orprovided to the Company, (ii) shall have provided to the Company itswritten agreement (x) to indemnify the Company and each of its officers,directors and agents against, and to hold the Company and its officers,directors and agents harmless from, any losses, claims, damages, expenses orliabilities (including reasonable attorneys fees) to which the Company or anyof its officers, directors or agents may become subject by reason of anystatement or omission in the registration statement made in reliance upon, orin conformity with, a written statement by such Holder furnished pursuanthereto or any failure of Holder to comply with the provisions of this Section 12,and (y) to report to the Company sales made pursuant to the registrationstatement.

 

13.                                 Security Interest.  The Company’s obligations underthis Note and the other Offered Notes are secured by a grant of, and theCompany does hereby grant to the Holder (and has similarly granted or is orwill similarly grant to the other Offered Noteholders in respect of theobligations under the other Offered Notes), subject to the terms, provisionsand limitations hereof, a security interest in (the “Collateral”) all tangibleand intangible assets of the Company now existing or hereafter arising(together with products and proceeds), *otherthan and in any event excluding* :

 

(i) all tangible andintangible assets which are the subject of any security interest previouslygranted by the Company which would prohibit or conflict with a grant of asecurity interest hereunder or under the other Offered Notes, and in any eventand without regard to whether or not so prohibited or conflicting, excludingall tangible and intangible assets which are the subject of a security interestpreviously granted by the Company in favor of Boston Scientific Corporation,and

 

5

----

 

(ii) whether now orhereafter existing or arising, all (a) leases and other contracts, (b) licenses(including licenses to software and intellectual property), (c) rights ofthe Company under such leases, other contracts and licenses, (d) property,if any, that is or becomes the subject of such leases, other contracts orlicenses, and (e) without limiting (a) through (c), collaborativearrangements by and between the Company and any third party and any and allinterests or rights of the Company in respect of the assets related thereto.

 

The security interestgranted hereby, and any corresponding lien, is and shall be further subject andsubordinate to any security interest and lien granted by the Company in theCollateral and established at any time or from time to time in the future aspart of any financing arrangements that may be entered into by and between theCompany and any bank or financial institution, and shall rank pari passu andshall be deemed hereby and thereby to be spread with the security interestsotherwise granted and liens established or created in the Collateral pursuantto or as contemplated by the other Offered Notes or any other convertible debtsecurities of the Company as may be issued from time to time and which soexpressly provide, and the Holder by accepting this Note does hereby expresslyconsent thereto, it being the intention of the Company and the Holder that thesecurity interest hereby granted, and any corresponding lien established orcreated, shall rank in right of priority (subject in any event to the limitsand exclusions otherwise herein provided) in respect of the Collateral senioronly to the general unsecured indebtedness and other unsecured obligations ofthe Company now or hereafter existing, pari passu with the security interestsgranted and liens established or created pursuant to or as contemplated by theother Offered Notes and any other convertible debt securities of the Company asmay be issued from time to time and which so expressly provide, and junior toany other lien created or security interest granted by the Company.

 

In the event Companyfails to perform any of its repayment obligations under this Note, and suchdefault is continuing for a period of 10 business days after written noticefrom Holder to the Company (“Default”), Holder may accelerate repayment of thePrincipal plus any accrued interest and exercise, without further notice, allrights and remedies under this Note or enforce any rights otherwiseavailable.  In the case of such Default, Holder shall give the Company notless than 60 business days prior written notice of its intended disposition ofthe Collateral; provided, however, if Company cures such Default priorto expiration of such notice period, Default will be not deemed to haveoccurred and Holder shall have no rights to accelerate repayment or enforce theCollateral.  For the purpose of enforcing any and all rights and remediesunder this Note, Holder may (i) require the Company to, upon Holder’s easonablerequest, assemble all or any part of the Collateral as directed by the Holderand make it available to Holder during normal business hours at the Company’sheadquarters, (ii) to the extent permitted by applicable law, enter,without breach of the peace, any premises where any such Collateral is or maybe located and, reasonably seize and remove such Collateral from such premises,(iii) direct the Company to reasonably provide relevant information fromthe Company’s books and records relating to the Collateral, and (iv) priorto the disposition of any of the Collateral, store or transfer the Collateral,process, repair or recondition such Collateral or otherwise prepare it fordisposition in any manner and to the extent Holder deems reasonablyappropriate.  Notwithstanding anything to the contrary herein, thesecurity interest granted hereby is expressly limited to the Final PaymentAmount outstanding under this Note and Holder shall exercise the foregoingrights in such a fashion so as to minimize disruption to Company and itsbusiness operations and only to the extent necessary to recover such unpaidFinal Payment Amount.  Holder and the Company shall work in good faith toeffectuate the intent of the previous sentence.  The security interestgranted hereby and any corresponding lien created or established, shallterminate and expire upon payment in full of the Final Payment Amount or uponthe occurrence of the Conversion Date, which ever first occurs, and withoutfurther action on the part of the Company or Holder.  Holder will executeany documents or instruments the Company may reasonably request to evidencesuch expiration.  All rights and remedies of the Holder hereunder shall beexercised in a manner which recognizes rights of the other Offered Noteholdersin respect of the Collateral and in respect of the lien and payment priorityprovided for hereunder.

 

By acceptance of thisNote, Holder acknowledges and agrees that (i) certain assets of theCompany are excluded from the security interest granted hereby, (ii) thesecurity interest granted to Holder

 

6

----

 

pursuant hereto, and any corresponding lien created orestablished, is and shall be subject and subordinate to any lien and securityinterest heretofore or hereafter granted by the Company or created andestablished as part of any financing arrangement that may be entered into byand between the Company and any bank or financial institution and, subject inany event to the limits and exclusions otherwise herein provided, such lien andsecurity interest shall rank senior only to the general unsecured indebtednessand other unsecured obligations of the Company now or hereafter existing, (iii) theCompany is issuing or may issue the other Offered Notes, and in additionthereto may also issue from time to time in the future other convertible debtsecurities, and has granted or may grant in connection with the issuance of theother Offered Notes or such other convertible debt securities, securityinterests in the Collateral which may, and the lien in respect of which may,rank pari passu in priority with the security interest granted hereby, andHolder does hereby consent to the grant by the Company of such securityinterests and the establishment and creation of such liens.  Holder shallperform, from time to time, such acts, and shall execute, acknowledge and/ordeliver such other instruments, documents and agreements as the Companyreasonably may request in order to consummate the transactions provided for inthis Note.  Without limiting the foregoing, by accepting this Note theHolder does expressly consent to the aforesaid ranking in respect of lien priorityand subordination and agrees to perform, from time to time, such acts, and toexecute, acknowledge and/or deliver such instruments, documents and agreements,as may from time to time be requested by the Company, or as may from time totime otherwise be reasonably requested, necessary or required, to so confirm orprovide.

 

14.                                 Miscellaneous.  No modification, rescission,waiver, forbearance, release or amendment of any provision of this Note shallbe made, except by a written agreement duly executed by each of the Company andHolder.  This Note may not be conveyed, assigned or transferred by Holderwithout the prior written consent of the Company.  Any permittedsubsequent Holder of this Note shall be deemed, by accepting this Note, to havemade and reaffirmed to the Company each and every of the acknowledgements,consents, agreements, representations, warranties and covenants of the originalHolder hereof.  All notices hereunder shall be in writing and be deemedgiven if personally delivered, sent by overnight courier (provided proof ofdelivery is received) or sent by telecopy (provided a confirmation oftransmission is received) at the addresses of the respective parties set forthin the initial paragraph of this Note or such other address as either partyshall notify the other of from time to time.  The Company hereby submitsto personal jurisdiction in the State of Maryland, consents to the jurisdictionof any competent state or federal district court sitting in the County ofMontgomery County, Maryland, and waives any and all rights to raise lack ofpersonal jurisdiction as a defense in any action, suit or proceeding inconnection with this Note or any related matter.  This Note shall begoverned by, and construed and interpreted in accordance with, the laws of theState of Maryland, without reference to conflicts of law provisions of suchstate.

 

IN WITNESS WHEREOF, the undersigned have caused thisNote to be executed and delivered by a duly authorized officer as of the datefirst above written.

 
| ** **                                    | **Osiris  Therapeutics, Inc.** |
|-----------------------------------------------|-------------------------------------|
| ** **                                    | ** **                          | ** ** |
| ** **                                    | ** **                          | ** ** |
| ** **                                    | By:                                 |   |
| ** **                                    | Name:                               |   |
| ** **                                    | Title:                              |   |
| ** **                                    |                                |   |
| ACCEPTED as of  the date first above written: |                                |   |
|                                          |                                |   |
| **Holder:**                                   |                                |   |
| ** **                                    |                                |   |
| ** **                                    |                                |   |
| By:                                           |                                |   |   |   |
| Name:                                         |                                |   |
| Title:                                        |                                |   |
|                                               |                                     |  |  |  |

 

7

----